The Latest Breaking News from Lilly

The S&P 500 and Nasdaq led a strong market rally this week as inflation fears wane. Salesforce, Delta Air Lines, JPMorgan were key newsmakers

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

New data from an experimental drug being developed by Eli Lilly & Co. raises an intriguing question about obesity treatments: How low can the weight loss go?

Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.